SWITCHING FROM INFLIXIMAB ORIGINATOR TO A BIOSIMILAR DOES NOT AFFECT PHARMACOKINETICS, IMMUNOGENICITY AND EFFICACY IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
van Hoeve, Karen
Dreesen, Erwin
Hoffman, Ilse
Ferrante, Marc
Ann, Gils
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
879
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [31] Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease
    Casanova, M. J.
    Chaparro, M.
    Nantes, O.
    Varela, P.
    Vela-Gonzalez, M.
    Montserrat, R.
    Sierra, O. G.
    Riestra, S.
    Barreiro-de Acosta, M.
    Martin-Rodriguez, M. M.
    Gargallo-Puyuelo, C. J.
    Reygosa, C.
    Munoz, R.
    Garcia de la Filia-Molina, I.
    Nunez-Ortiz, A.
    Kolle, L.
    Calafat, M.
    Huguet, J. M.
    Iglesias-Flores, E.
    Martinez-Perez, T. J.
    Bosch, O.
    Duque-Alcorta, J. M.
    Frago-Larramona, S.
    Sanchez-Azofra, M.
    Van Domselaar, M.
    Gonzalez-Cosano, V. M.
    Bujanda, L.
    Rubio, S.
    Mancebo, A.
    Castro, B.
    Garcia-Lopez, S.
    de Francisco, R.
    Nieto, L.
    Laredo, V.
    Gutierrez, A.
    Mesonero, F.
    Leo-Carnerero, E.
    Canete, F.
    Ruiz, L.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I474 - I475
  • [32] Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort
    Chanchlani, Neil
    Mortier, Kajal
    Williams, Linda J.
    Muhammed, Rafeeq
    Auth, Marcus K. H.
    Cosgrove, Mike
    Fagbemi, Andrew
    Fell, John
    Chong, Sonny
    Zamvar, Veena
    Hyer, Warren
    Bisset, W. Michael
    Morris, Mary-Anne
    Rodrigues, Astor
    Mitton, Sally G.
    Bunn, Su
    Beattie, R. Mark
    Willmott, Anne
    Wilson, David C.
    Russell, Richard K.
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2018, 67 (04): : 513 - 519
  • [33] Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease
    Lovero, Rosa
    Losurdo, Giuseppe
    La Fortezza, Rosa Federica
    Terracciano, Fulvia
    Biscaglia, Giuseppe
    Martino, Giuseppina
    Nardella, Marianna
    Di Leo, Alfredo
    Principi, Mariabeatrice
    Andriulli, Angelo
    Bossa, Fabrizio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 201 - 207
  • [34] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Peeyush Kumar
    Sudheer K. Vuyyuru
    Bhaskar Kante
    Saurabh Kedia
    Pabitra Sahu
    Mukesh Kumar Ranjan
    Sandeep Mundhra
    Rithvik Golla
    Mukesh Kumar
    Shubi Virmani
    Anvita Gupta
    Nidhi Yadav
    Govind Makharia
    Vineet Ahuja
    Indian Journal of Gastroenterology, 2022, 41 : 446 - 455
  • [35] Efficacy and Safety of Nonmedical Switching From Infliximab Originator to Infliximab Biosimilar CT-P13 in Patients With Inflammatory Bowel Disease, A Single-Center Prospective Study in Japan
    Takeda, Teruyuki
    Takahashi, Atsushi
    Mikumo, Hiroyuki
    Kinjo, Ken
    Yasukawa, Shigeyoshi
    Koga, Akihiro
    Takatsu, Noritaka
    Hisabe, Takashi
    Arima, Hisatomi
    Imakiire, Sou
    Yamauchi, Eri
    Yao, Kenshi
    Hirai, Fumihito
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S11 - S11
  • [36] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [37] Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
    Yuksel, I.
    Baspinar, B.
    Durak, M. B.
    Kilic, V.
    Kivrakoglu, F.
    Guven, I. E.
    Kosar, K.
    Erdogan, C.
    Alkan, A.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I487 - I487
  • [38] Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis
    Kumar, Peeyush
    Vuyyuru, Sudheer K.
    Kante, Bhaskar
    Kedia, Saurabh
    Sahu, Pabitra
    Ranjan, Mukesh Kumar
    Mundhra, Sandeep
    Golla, Rithvik
    Kumar, Mukesh
    Virmani, Shubi
    Gupta, Anvita
    Yadav, Nidhi
    Makharia, Govind
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2022, 41 (05) : 446 - 455
  • [39] RAPID 30-MINUTE INFLIXIMAB INFUSION PROTOCOLS ARE SAFE AND EFFECTIVE WHEN SWITCHING INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS FROM ORIGINATOR TO BIOSIMILAR INFLIXIMAB
    Srinivasan, Ashish
    van Langenberg, Daniel R.
    Haar, Geoffrey
    Miller, Caroline
    Rodrigues, Beverly
    GASTROENTEROLOGY, 2019, 156 (06) : S633 - S634
  • [40] Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease
    Haghnejad, Vincent
    Le Berre, Catherine
    Dominique, Yoann
    Zallot, Camille
    Guillemin, Francis
    Peyrin-Biroulet, Laurent
    DIGESTIVE AND LIVER DISEASE, 2020, 52 (03) : 281 - 288
12345